Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Financing Activities (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Cash from Financing Activities readings, the most recent being -$4.0 million for Q4 2025.

  • Quarterly Cash from Financing Activities fell 235.48% to -$4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.9 million through Dec 2025, up 86.82% year-over-year, with the annual reading at -$4.7 million for FY2025, 90.89% up from the prior year.
  • Cash from Financing Activities hit -$4.0 million in Q4 2025 for Oramed Pharmaceuticals, down from -$361000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $80.6 million in Q3 2021 and bottomed at -$30.6 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $11.5 million, with a median of $2.3 million recorded in 2022.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 10234.98% in 2021 before it crashed 881.89% in 2024.
  • Oramed Pharmaceuticals' Cash from Financing Activities stood at $60.6 million in 2021, then tumbled by 93.11% to $4.2 million in 2022, then tumbled by 698.8% to -$25.0 million in 2023, then soared by 95.22% to -$1.2 million in 2024, then crashed by 235.48% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash from Financing Activities are -$4.0 million (Q4 2025), -$361000.0 (Q3 2025), and -$1.2 million (Q4 2024).